Aether Industries Ltd

- The company currently has no plans for any new fundraise via debt or equity. - The existing debt is primarily working capital debt, which is short-term and expected to continue for the next couple of years unless internal accruals improve. - Management indicated that they are not planning any additional equity or long-term debt fundraise currently. - Working capital debt will persist to manage operational needs; no long-term debt repayment plan was specified beyond utilizing internal cash flows.

- FY '26 capex target is INR 350 crores. - Around INR 100-150 crores of capex will be invested in Site 5 (Panoli). - Site 3++ (dedicated to Milliken) will see INR 200-250 crores capitalized this fiscal, expected to commence production by Q4 FY '26. - Site 5 construction is on track; first two production blocks targeted for completion by end of Q3 FY '26. - Capex cost per plant at Site 5 is approx. INR 160-180 crores with an expected asset turn of 1.75x at maturity. - R&D expansion with an investment of INR 30-40 crores planned to increase number of labs and fume hoods. - Multipurpose plant designs allow flexibility with minimal capex (~less than INR 50 lakh) to switch chemistries. - Future projects and ramp-up at Sites 3++, 4 (Baker Hughes), and 5 are strategic growth drivers.

Future Growth Expectations of Aether Industries Limited: - Sales revenue grew 35% YoY in Q1 FY '26, indicating strong growth momentum. - Large-Scale Manufacturing (LSM) segment growing at 9% YoY and 8% QoQ, with stable product prices and margins. - Contract/Exclusive Manufacturing (CEM) business ramping up, notably Baker Hughes contract contributing significantly with revenues rising from INR25 crores in Q4 to INR41 crores in Q1. - Site-5 capex of INR100-150 crores planned, expected to drive future volume and revenue growth with new plants coming online by end of calendar year. - Milliken contract to be commercialized in FY '26 with expectations of good ramp-up in FY '27. - Pipeline includes 12-18 projects in advanced stages, likely to close within 4-6 months, supporting rapid growth. - Target to reduce working capital cycle to ~150-170 days by FY '27 to improve operational efficiency. - Overall bullish outlook driven by increased R&D projects, new client additions, and expansion in material science and sustainability sectors.

- Aether Industries expects strong growth driven by new projects and site expansions, notably Site 3++ (Milliken contract), Site-4 (Baker Hughes), and Site-5. - The company is rapidly commercializing new molecules with a faster customer contract timeline (now 6 months to 1 year). - EBITDA margins remain robust (~30%), and PAT rose 57% YoY in Q1 FY '26. - Volume growth is strong across LSM, CEM, and CRAMS segments despite price pressure due to Chinese dumping. - Capex of INR 300-350 crores in FY '26 will support capacity expansion and R&D, enabling growth. - Working capital cycle reduction target to ~165 days aims for better operating efficiency. - While no forward revenue/profit guidance given, management anticipates these new contracts and sites will be primary growth drivers in FY '26 and FY '27. - Increasing customer wallet share with innovative, India-made specialty chemicals fuels long-term profitability.

- Aether Industries currently has approximately 12 to 18 projects with various customers, including Milliken, that are in advanced stages or near finalization. - The negotiation cycle for contracts like Milliken has shortened significantly from earlier timelines of 1 to 1.5 years down to 4 to 6 months, indicating faster closure of new orders. - The company is fast-tracking several new contracts and projects, including those at Site 3++, Site-4 (Baker Hughes), and Site-5, which are expected to contribute to revenue growth over the next 18 months. - Capacity-wise, smaller orders (under 100-200 tons) can be accommodated in existing sites (Site-2, Site-3), while larger bulk contracts (200-500+ tons) will be handled at Site-5. - The company continues to add new clients, with six new clients added in Q1 FY '26, indicating a healthy pipeline of pending orders and new business opportunities.